Toripalimab plus chemotherapy demonstrates improvement in co-primary endpoints of PFS and OS in patients with advanced ESCC -
- PFS and OS benefits were observed across all PD-L1 expression subgroups, including in patients with low PD-L1 expression -
https://finance.yahoo.com/news/coherus-junshi-biosciences-announce-positive-130000417.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.